サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1376007

重症筋無力症治療の市場規模、シェア、動向分析レポート：治療タイプ別、最終用途別、地域別、セグメント予測、2023年～2030年

Myasthenia Gravis Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Thymectomy, Cholinesterase Inhibitors, Rapid Immunotherapies), By End-use (Hospitals, Clinics), By Region and Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 120 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
重症筋無力症治療の市場規模、シェア、動向分析レポート：治療タイプ別、最終用途別、地域別、セグメント予測、2023年～2030年
出版日: 2023年10月25日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

重症筋無力症治療市場の成長と動向：

Grand View Research社の最新レポートによると、重症筋無力症治療の世界市場規模は2030年までに42億6,000万米ドルに達する見込みです。

2023年から2030年までのCAGRは9.0％で拡大する見込みです。希少疾患に対する認識の高まり、生物製剤の出現、免疫療法＆免疫抑制剤の採用拡大が重症筋無力症（MG）治療市場を牽引しています。

重症筋無力症（MG）は、抗体を介した神経筋伝達障害によって引き起こされるまれな自己免疫疾患で、骨格筋の筋力低下をもたらします。本疾患に関連する障害には、眼瞼下垂、複視、歩行障害、会話障害などがあります。MG患者は無痛性の筋力低下を呈し、繰り返し使用すると悪化し、安静にしていると改善します。

米国希少疾病対策機構（NORD）によると、米国では10万人に14～40人が重症筋無力症に罹患しています。報告によると、重症筋無力症の頻度はここ数十年で増加傾向にあります。これは、患者の特定が容易になったことと、世界中の一般市民の間で自己免疫疾患の有病率が増加していることに起因しています。重症筋無力症は男性よりも女性に多く発症し、症状はどの年齢でも現れるが、通常、男性では50～60歳代、女性では20～30歳代に発症のピークを迎えます。

治療分野では薬物療法が最大の市場シェアを占めており、予測期間中も市場の主導的地位を維持すると予想されています。というのも、薬物療法は症状をほぼ管理し、免疫系を劇的に抑制することができるからです。薬物療法には、ソリリス（エクリズマブ）などの免疫療法、コルチコステロイド、プログラフ（タクロリムス）やネオーラル/サンディミュン（シクロスポリン）などの免疫抑制剤が含まれます。しかし、新興諸国や低開発諸国では治療費が高く、認知度が低いため、市場の成長が阻害されると予想されます。

重症筋無力症治療市場の成長と動向：

  • 薬物療法は免疫系を劇的に抑制し、関連する症状をほぼ抑えることができます。薬物療法には、ソリリス（エクリズマブ）などの免疫療法、コルチコステロイド、プログラフ（タクロリムス）やネオーラル/サンディミュン（シクロスポリン）などの免疫抑制剤が含まれます。
  • モノクローナル抗体セグメントは、重症筋無力症治療における高い精度と優れた有効性により、2022年には60％以上の最大市場シェアを占め、予測期間中も主導的地位を維持すると予想されます。
  • 最終用途に基づき、市場は病院、診療所、その他に区分されます。病院分野は2022年に約55％の最大市場シェアを占め、予測期間には9.0％の有利なCAGRで成長する見込みです。
  • 2022年、北米は50％を超える最大の市場シェアを持ち、予測期間を通じて市場をリードすると予測されています。
  • アジア太平洋地域は、免疫抑制剤やモノクローナル抗体などの医薬品による収益の増加により、予測期間を通じて有利なCAGRで成長すると予測されます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 重症筋無力症治療市場の変数、動向および範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 重症筋無力症治療市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 重症筋無力症治療：治療タイプの推定・動向分析

  • 重症筋無力症治療市場：重要なポイント
  • 重症筋無力症治療市場：動向と市場シェア分析、2022年および2030年
  • コリンエステラーゼ阻害剤
    • コリンエステラーゼ阻害剤市場推計・予測、2018年から2030年まで
  • 慢性免疫調節薬
    • 慢性免疫調節薬市場推計・予測、2018年から2030年まで
  • モノクローナル抗体
    • モノクローナル抗体市場推計・予測、2018年から2030年まで
  • 迅速免疫療法
    • 迅速免疫療法市場推計・予測、2018年から2030年まで
  • 胸腺切除術
    • 胸腺摘出市場推計・予測、2018年から2030年まで
  • その他
    • その他の市場推計・予測、2018年から2030年まで

第5章 重症筋無力症治療：最終用途の推定・動向分析

  • 重症筋無力症治療市場：重要なポイント
  • 重症筋無力症治療市場：動向と市場シェア分析、2022年および2030年
  • 病院
  • クリニック
  • その他

第6章 重症筋無力症治療市場：地域の推定・動向分析

  • 地域別の見通し
  • 地域別の重症筋無力症治療市場：主要マーケットプレースのポイント
  • 北米
    • 市場推計・予測、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • スウェーデン
    • ノルウェー
    • デンマーク
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 市場参入企業の分類
    • Alexion Pharmaceutical Inc.
    • Grifols SA
    • Avadel Pharmaceuticals, Plc.
    • Novartis
    • Pfizer, Inc.
    • AbbVie Inc.
    • F.Hoffmann-La Roche AG
    • GlaxoSmithKline Plc.
    • Bausch Health Companies Inc.
    • Shire plc
図表

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 3 North America myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 4 North America myasthenia gravis treatment market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 6 U.S. myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 7 Canada myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 8 Canada myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Europe myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 10 Europe myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Europe myasthenia gravis treatment market, by region, 2018 - 2030 (USD Million)
  • Table 12 Germany myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 13 Germany myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 14 UK myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 15 UK myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 16 France myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 17 France myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 18 Italy myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 19 Italy myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 20 Spain myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 21 Spain myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 22 Sweden myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 23 Sweden myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Norway myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 25 Norway myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 26 Denmark myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 27 Denmark myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific myasthenia gravis treatment market, by region, 2018 - 2030 (USD Million)
  • Table 31 China myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 32 China myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 33 Japan myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 34 Japan myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 35 India myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 36 India myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 37 Australia myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 38 Australia myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 39 Thailand myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 40 Thailand myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 41 South Korea myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 42 South Korea myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Latin America myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 44 Latin America myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 45 Latin America myasthenia gravis treatment market, by region, 2018 - 2030 (USD Million)
  • Table 46 Brazil myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 47 Brazil myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 48 Mexico myasthenia gravis treatment market, by treatment, type 2018 - 2030 (USD Million)
  • Table 49 Mexico myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 50 Argentina myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 51 Argentina myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 53 Middle East and Africa myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 54 Middle East and Africa myasthenia gravis treatment market, by region, 2018 - 2030 (USD Million)
  • Table 55 South Africa myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 56 South Africa myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 59 UAE myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 60 UAE myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 61 Kuwait myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 62 Kuwait myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Myasthenia gravis treatment: Market outlook
  • Fig. 9 Myasthenia gravis treatment: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Myasthenia gravis treatment market driver impact
  • Fig. 15 Myasthenia gravis treatment market restraint impact
  • Fig. 16 Myasthenia gravis treatment market strategic initiatives analysis
  • Fig. 17 Myasthenia gravis treatment market: Treatment type movement analysis
  • Fig. 18 Myasthenia gravis treatment market: Treatment type outlook and key takeaways
  • Fig. 19 Cholinesterase inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Chronic immunomodulators market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Monoclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Rapid immunotherapies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Thymectomy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Myasthenia gravis treatment market: End use movement analysis
  • Fig. 26 Myasthenia gravis treatment market: End use outlook and key takeaways
  • Fig. 27 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Clinics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Global myasthenia gravis treatment market: Regional movement analysis
  • Fig. 31 Global myasthenia gravis treatment market: Regional outlook and key takeaways
  • Fig. 32 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68038-002-6

Myasthenia Gravis Treatment Market Growth & Trends:

The global myasthenia gravis treatment market size is expected to reach USD 4.26 billion by 2030, according to a new report by Grand View Research, Inc.. It is expected to expand at a CAGR of 9.0% from 2023 to 2030. Increasing awareness of rare diseases, emergence of biologics, and growing adoption of immunotherapies & immunosuppressants are driving the myasthenia gravis (MG) treatment market.

Myasthenia gravis (MG) is a rare autoimmune disorder caused by an antibody mediated neuromuscular transmission obstruction that results in skeletal muscle weakness. Some of the disorders associated with the disease include drooping eyelids, double vision, trouble walking, and trouble talking. Patients with MG present with painless muscle weakness that worsens with repeated use and improves with rest.

According to the National Organization for Rare Disorders (NORD), in the U.S. around 14-40 per 100,000 individuals suffer from myasthenia gravis. Reports suggest that the frequency of the disorder is on the rise over the last several decades. This can be attributed to the better identification of patients and the increasing prevalence of autoimmune disorders among general public across the world. Myasthenia gravis occurs more frequently in females than in males, and although symptoms may appear at any age, its onset usually peaks in men in their 50s or 60s and in women during their 20s or 30s.

Medication held the largest market share in the treatment segment and is expected to maintain its market leading position through the forecast period. This is because medications can largely manage the symptoms and dramatically inhibit the immune system. Medications include immunotherapies such as Soliris (eculizumab), corticosteroids, and immunosuppressive drugs such as Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine). However, high cost of treatment and lack of awareness in the developing & underdeveloped countries are expected to inhibit the market growth.

Myasthenia Gravis Treatment Market Growth & Trends:

  • Medications can dramatically inhibit the immune system and largely manage the associated symptoms. Medications include immunotherapies such as Soliris (eculizumab), corticosteroids, and immunosuppressive drugs such as Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine).
  • The monoclonal antibodies segment held the largest market share of over 60% in 2022 and is expected to maintain its leading position through the forecast period, owing to the high precision in treating myasthenia gravis and better efficacy.
  • Based on end use, the market has been segmented into hospitals, clinics, and others. The hospital segment held the largest market share of around 55% in 2022 and is expected to grow at a lucrative CAGR of 9.0% over the forecast period.
  • In 2022, North America had the largest market share of over 50% and is projected to lead the market throughout the forecast period.
  • Asia Pacific is anticipated to grow at a lucrative CAGR through the forecast period due to the increase in revenue generation from medications such as immunosuppressants and monoclonal antibodies in this region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Treatment Type
    • 1.1.2. End use
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment outlook
    • 2.2.2. End use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Myasthenia Gravis Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Myasthenia Gravis Treatment Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Myasthenia Gravis Treatment: Treatment Type Estimates & Trend Analysis

  • 4.1. Myasthenia Gravis Treatment Market: Key Takeaways
  • 4.2. Myasthenia Gravis Treatment Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Cholinesterase Inhibitors
    • 4.3.1. Cholinesterase inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Chronic Immunomodulators
    • 4.4.1. Chronic immunomodulators market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Monoclonal Antibodies
    • 4.5.1. Monoclonal antibodies market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Rapid Immunotherapies
    • 4.6.1. Rapid immunotherapies market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7. Thymectomy
    • 4.7.1. Thymectomy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Myasthenia Gravis Treatment: End Use Estimates & Trend Analysis

  • 5.1. Myasthenia Gravis Treatment Market: Key Takeaways
  • 5.2. Myasthenia Gravis Treatment Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Hospitals
    • 5.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Clinics
    • 5.4.1. Clinics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Myasthenia Gravis Treatment Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Myasthenia Gravis Treatment Market by Region: Key Marketplace Takeaway
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Sweden
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Norway
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. Saudi Arabia
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. Alexion Pharmaceutical Inc.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Grifols SA
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Avadel Pharmaceuticals, Plc.
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Novartis
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Pfizer, Inc.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. AbbVie Inc.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. F.Hoffmann-La Roche AG
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. GlaxoSmithKline Plc.
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Bausch Health Companies Inc.
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. Shire plc
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives